Others - Nomos eLibrary

Jump to content

Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? / Others

Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? / Others

Contents
- Chapter Expand | CollapsePage
- 2–10 Titelei/Inhaltsverzeichnis 2–10
- 11–12 Acronyms and Abbreviations 11–12
- 13–15 I. Introduction 13–15
- 16–20 II. Background 16–20
  - 16–18 A. Pharmaceutical Industry – The Development of a New Drug. 16–18
  - 18–19 B. New Drug Approval Regulations 18–19
  - 19–20 C. Generic Drugs Approval. 19–20
- 21–41 III. Case Studies-Facts 21–41
  - 21–32 A. Taxotere 21–32
  - 32–41 B. Xalatan 32–41
- 42–72 IV. Discussion 42–72
- 73–76 V. Final Remarks 73–76
- 77–84 List of works cited 77–84
  - 77–80 Periodical Materials in English 77–80
  - 80–80 Periodical Material in German 80–80
  - 80–80 Non Periodical Material 80–80
  - 80–81 Table of books 80–81
  - 81–82 Table of Cases 81–82
    - 81–81 European Union 81–81
    - 81–81 EPO Board of Appeal 81–81
    - 81–81 France 81–81
    - 81–81 Germany 81–81
    - Italy
    - 82–82 United Kingdom 82–82
    - 82–82 United States 82–82
  - 82–83 Statutes 82–83
  - 83–83 Speeches and Reports 83–83
  - 83–83 Press release 83–83
  - 83–84 Others 83–84
Durchsuchen Sie das Werk
Geben Sie ein Keyword in die Suchleiste ein
CC-BY Access

Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? , page 83 - 84

Others

Autoren

Monica Donghi

DOI
- doi.org/10.5771/9783845251288-83-1-2
- ISBN print: 978-3-8487-0991-5
- ISBN online: 978-3-8452-5128-8
Chapter Preview

Chapter Preview
Share

Contact
About us
Feedback
Privacy Policy
FAQ
Terms
Legal Details

© 2024 Nomos Verlagsgesellschaft mbH & Co. KG

Share by email Nomos eLibrary

Recipient*

Sender*

Message*

Your name

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.